SUDARSHAN PHARMA INDUSTRIES
|
|
| BOM : 543828     NSE :      | |
| LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
| ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : None or < 25% |
Jul 22,2026 |
|
Price(EOD): ₹ 40.20
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 1,003.79 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| SUDARSHAN PHARMA INDUSTRIES | -0.3% | 7.3% | 47.1% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.4% | 4.3% | 13.6% |
| DIVIS LABORATORIES | 0.9% | 8.9% | 8% |
| TORRENT PHARMACEUTICALS | 0.7% | 13% | 46.5% |
| CIPLA | -1% | -0% | -3.9% |
| DR REDDYS LABORATORIES | -3.3% | -8.4% | -4.3% |
| MANKIND PHARMA | -0% | 0.3% | -2.8% |
| LUPIN | -3.8% | 2.8% | 28.9% |
| ZYDUS LIFESCIENCES | -2.1% | 4.2% | 18.3% |
FUNDAMENTAL ANALYSIS OF SUDARSHAN PHARMA INDUSTRIES
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SUDARSHAN PHARMA INDUSTRIES
 | Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
42.95
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 23.37 Cr
[Latest Qtr - Mar2026 - Consolidated Results ] 6.47
P/B Calculated based on Book Value of Rs 155.10 Cr
[Latest Year - Mar2026 - Consolidated Results ] 1.43
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 703.06 Cr
[Latest Qtr - Mar2026 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
895% NA (-ve EV) 170% |
SHARE PRICE MOMENTUM OF SUDARSHAN PHARMA INDUSTRIES
SUDARSHAN PHARMA INDUSTRIES vs SENSEX
DEBT OF SUDARSHAN PHARMA INDUSTRIES
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2025 2024 2023 Avg_3yrs |
1.36 0.96 0.34 0.89 |
1.34 0.94 0.34 0.87 |
|
[Last Annual Data : Mar2025]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF SUDARSHAN PHARMA INDUSTRIES
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Mar2026 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF SUDARSHAN PHARMA INDUSTRIES
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
31.5% 85.8% 202.12% 174.64% |
36.71% 26.78% 58.77% 53.68% |
| QtrlyTrend |
8 | |
| Latest Qtr: Mar2026 | ||
| Quarterly Result Analysis → | ||
SUDARSHAN PHARMA INDUSTRIES related INDICES
You may also like the below Video Courses
FAQ about SUDARSHAN PHARMA INDUSTRIES
Is SUDARSHAN PHARMA INDUSTRIES good for long term investment?
As on Jul 22,2026, the Fundamentals of SUDARSHAN PHARMA INDUSTRIES look Poor and hence it may not be good for long term investment ! See Financial Performance of SUDARSHAN PHARMA INDUSTRIES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SUDARSHAN PHARMA INDUSTRIES UnderValued or OverValued?
As on Jul 22,2026, SUDARSHAN PHARMA INDUSTRIES is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of SUDARSHAN PHARMA INDUSTRIES ?
As on Jul 22,2026, the Intrinsic Value of SUDARSHAN PHARMA INDUSTRIES is Rs. 9.47 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 4.04
Fair Value [Median EV / Sales Model] : Rs. -1.65
Fair Value [Median Price / Sales Model] : Rs. 14.89
Estimated Median Fair Value of SUDARSHAN PHARMA INDUSTRIES : Rs. 9.47
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.